Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $125 | $86 | $82 | $51 |
| G&A Expenses | $18 | $19 | $25 | $20 |
| SG&A Expenses | $18 | $19 | $25 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $142 | $105 | $107 | $71 |
| Operating Income | -$142 | -$105 | -$107 | -$71 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $13 | $8 | $2 | $0 |
| Pre-Tax Income | -$129 | -$97 | -$105 | -$71 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$129 | -$97 | -$105 | -$71 |
| % Margin | – | – | – | – |
| EPS | -2.2 | -2.14 | -2.62 | -1.79 |
| % Growth | -2.8% | 18.3% | -46.4% | – |
| EPS Diluted | -2.2 | -2.14 | -2.62 | -1.79 |
| Weighted Avg Shares Out | 59 | 45 | 40 | 40 |
| Weighted Avg Shares Out Dil | 59 | 45 | 40 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $8 | $2 | $0 |
| Interest Expense | $0 | – | $0 | – |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$142 | -$105 | -$107 | -$71 |
| % Margin | – | – | – | – |